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S256 Poster Session IITo address this, non-irradiated female BALB/C mice were trans-
planted with 5-6107 whole bone marrow (WBM) cells from male
BALB/C mice daily for four day on week zero, then again on week
eight (4.5108 cells total/mouse), or an equal volume of diluent
(control). On week 24, transplanted mice received 1000 cGy of
chest-only radiation or no radiation. On week 32, histochemical
and immunohistochemical analyses were performed on recipient’s
lungs.
Bone marrow chimerism was not significantly different in the irra-
diated and non-irradiated cohorts at the time of sacrifice (average
45.11 + 6.25% Y chromosome+, all mice). Recipient lungs contained
few non-hematopoietic donor marrow-derived cells. These cells
were exclusively epithelial (Y+/cytokeratin+), primarily type II pneu-
mocytes (Y+/prosurfactant C+), while no endothelial (Y+/von Wille-
brand+) or vascular smooth muscle (Y+/alpha-actin+) cells were
identified. Irradiated and non-irradiated cohorts had similar quanti-
ties of these cells (0.80 + 0.22% vs. 0.51 + 0.08% Y+/cytokeratin+;
0.37 + 0.08% vs. 0.32 + 0.12% Y+/prosurfactant C+, p. 0.2). Pul-
monary vessel wall thickness-to-blood vessel diameter ratios
(PVWT/D) were significantly increased in the non-irradiated cohort
compared with controls and these ratios were further increased in the
irradiated cohort (141 + 5.75%, 161 + 5.34% of control, p\0.05
comparing all groups).
These data indicated that marrow cell infusion alone results in pul-
monary vascular remodeling, and this effect is augmented by radia-
tion injury. These changes are independent of transplanted
marrow cell conversion to pulmonary vascular endothelial, smooth
muscle cells. These studies suggest that transplanted cells may be
lung toxic entities in the setting of clinical BMT.266
MODELS OF STEM CELL TRANSPLANTATION FOR THE REPAIR OF NON-
HEMATOPOIETIC TISSUES
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Davis, Sacramento, CA
Human stem cells from adult sources have been shown, in our lab-
oratory and others, to promote the repair of damaged tissues. Differ-
ent populations of stem cells contribute to the regeneration of
muscle, neural tissue, liver, heart, and vasculature, although the
mechanisms by which they accomplish this are still not well under-
stood. We and others have shown that stem cells home to hypoxic
and/or inflamed areas, and release bioactive factors that can suppress
the local immune system, enhance angiogenesis, inhibit fibrosis and
apoptosis, and stimulate recruitment, retention, mitosis and differ-
entiation of endogenous tissue-residing stem cells. These trophic ef-
fects are distinct from the direct differentiation of stem cells into the
tissue to be regenerated. To actually rebuild a non-hematopoietic
tissue, the differentiated progeny of embryonic or induced pluripo-
tent stem cells will be required. We have focused on improving ro-
dent models in which to examine human stem cell-mediated
disease correction and tissue repair, focusing primarily on liver re-
generation and hypoxic tissue models of peripheral vascular disease
and cardiac ischemia. Most recently we are studying mesenchymal
stem cell–mediated repair of neural damage. We are interested in
the mechanisms by which stem cells of different types and origins
home preferentially into areas of tissue damage, and we seek to im-
prove the robustness. To track cells into the damaged tissues in
vivo, we have labeled them with fluorophore – conjugated iron oxide
nanoparticles and have used novel mouse models that facilitate hu-
man cell detection. We have also used 19F magnetic resonance im-
aging for stem cell tracking with multiple unique perfluorocarbon
nanobeacons, human/murine centromeric FISH, immunohisto-
chemistry and quantitative PCR. Using these technologies, we
have shown that human stem cells migrate from the bloodstream
randomly and in moderate numbers throughout all tissues examined
in cases of chronic disease or following sublethal irradiation, but that
in instances of acute damage, the homing is more vigorous and spe-
cific to the site of damage. Pre-culture in hypoxia dramatically alters
the phenotype and migratory characteristics of human mesenchymal
stem cells. We are applying this knowledge to tissue repair strategies,
to allow enhanced numbers of stem cells to migrate to the areas of
hypoxic damage, to exert trophic effects that initiate revasculariza-
tion and cascades of repair.SUPPORTIVE CARE
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of Texas M.D. Anderson Cancer Center, Houston, TX; 2University of
Texas M.D. Anderson Cancer Center, Houston, TX
Background:BK virus infection has been associated with late on-
set hemorrhagic cystitis (HC) after HSCT. Based on data sug-
gesting that cidofovir has activity against BK virus we treated
patients with symptomatic HC and high BK virus titers with ci-
dofovir, we now review the outcome of 32 patients undergoing
this therapy.
Patients andMethods: The patients studied had undergone alloge-
neic HSCT for leukemia (28), MDS (1), lymphoma (2), and ovarian
cancer (1), and presented with UTI symptoms including (any combi-
nation of) hematuria, urgency, and pain, and a high-titer of BK-virus.
Patients received treatment with either once weekly (1-5 mg/kg), or
divided 3  weekly/every other day (0.25-0.5 mg/kg/dose). All pa-
tients received forced hydration. On the once-weekly schedule 22/
23 patients received probenecid and 1/9 in the higher frequency
schedule received probenecid. Semi-quantitative BK virus assay
was performed prior to and following cidofovir.
Results: A total of 32 patients were treated and the median age was
44 years (range, 23-64), with 17 males and 15 females. Donors were
related (n5 13), unrelated (n5 11), haploidentical (n5 2), and un-
related cord blood (CB) (n5 6). The conditioning regimen was mye-
loablative in 23 pts (72%) and reduced intensity in 9 pts (28%). 24/32
pts (75%) had developed GVHD and were on steroids when diag-
nosed with BK-UTI. Cidofovir was well tolerated with no subjects
developing renal insufficiency. The majority of symptoms were re-
solved within 10 days from cidofovir initiation but the limited num-
ber of subjects precluded a formal comparison between dosing
subgroups (Table 1).
The viral load did not change significantly when assessed at a me-
dian of 24 days after start of cidofovir (median of$3.9 107 copies/
mL). However, patients who were re-assayed at later time points
(median 68 days) had a viral load less than 1% of the initial value (me-
dian 4.9105 copies/mL).
We conclude that cidofovir appears promising as treatment for
BK-virus related hemorrhagic cystitis. The frequent administra-
tion-schedule is relatively easy to administer without the need for
probenecid. More data are needed to determine an optimal cidofovir
dosing schedule, and optimal time to reassess BK virus load by PCR
in allogeneic HSCT patients.
Table 1. Hemorrhagic cystitis symptom response
Hematuria Urgency Cramp/Spasm Pain CBIPre Cidofovir 28 (88%) 27 (85%) 25 (78%) 30 (94%) 13 (41%)
Post Cidofovir 6 (18%) 9 (28%) 1 (3%) 9 (28%) 1 (3%)CBI5 continuous bladder irrigation.268
A PHASE 1 DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND
PHARMACOKINETICS OF PALIFERMIN IN PEDIATRIC SUBJECTS WITH
ACUTE LEUKEMIAS UNDERGOING MYELOABLATIVE THERAPY AND AL-
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